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Radiomics of Neurodegeneration in Alzheimer's: MRI, MRS, & PET
ABSTRACT
This work aims to review and assess the current state of Radiology research in Alzheimer’s Disease to complement and coordinate multi-modal research progress via Radiomics. Alzheimer’s Disease. Neuroimaging Initiative (ADNI) is a center that utilizes
the different standard methods for the use of clinical magnetic resonance imaging (MRI) and positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers for advancing. Early diagnosis and assessing the efficacy of treatment and related
biomarkers for Alzheimer's’ Disease. ADNI databases can be assessed to analyze the patterns and changes in imaging and CSF biomarker data with Mild Cognitive Impairment and Alzheimer’s Disease patients. The use and observation of biomarkers try to
either directly or indirectly measure the pathology of AD as a predictor of dementia or screen for early cognitive decline. These predictors will make it easier to select patients with mild impairment and healthy elderly patients for treatment and even
disease prevention trials. Proton magnetic resonance spectroscopy (1H-MRS) is a potential biochemical imaging marker for AD that can recognize patients with the disease prior to the onset of clinical symptoms. Changes in the concentration of a few
metabolites in MRS can serve as stand-in markers for pathogenic abnormalities in AD although 31P MRS is gaining ground at high field MRI centers. ADNI-MRI protocols have been adjusted to be compatible with the latest phase called ADNI-3 which
started in mid 2017. Regardless of the vendor, e.g., GE, Siemens, and Phillips, all protocols from the second phase ADNI-2 are used on the third phase ADNI-3 three Tesla models. The most critical MRI sequences used in screening for Alzheimer’s Disease
are T1 weighted, ASL, MP-RAGE, T2* GRE, 3D-FLAIR, High Resolution Hippocampus, DWI, and EPI-BOLD sequences. The advance in brain diffusion imaging (DWI) and Resting State functional MRI (RSfMRI) are emerging AD MRI tools. Tau PET, also known
as Tau Positron Emission Tomography, is a promising method for predicting cognitive abnormalities that is more accurate than amyloid PET and today’s MRI. It can support prognosis in the preclinical and prodromal stages of AD. It has demonstrated
remarkable diagnosis efficacy for differentiating non-AD neurodegenerative diseases from AD dementia.

INTRODUCTION

• The ADNI study examined patients with early mild
cognitive impairment (MCI), early AD, and normal
patients.(1)
• MRI measures of change were shown to be the most
effective outcome measures.(1)
• • MRI creates three-dimensional, precise anatomical
images of the body from inside by combining powerful
magnetic fields and radio waves.
• • AD is progressive neurological disorder in which nerve
cells in the peripheral nervous system gradually lose
function resulting in the brain to shrink and brain cells
to die.(2)
• MRS permits non-invasive in vivo metabolite
analysis and establishes a connection between the
biochemical change and the pathophysiology of AD.(2)

RESULTS

DISCUSSION

•
•
•
•
•
●
●

AD is an accumulation of β-amyloid plaques and neurofibrillary tangles made up of tau amyloid fibrils, causes
damage synapses leading to memory loss.(1)
Aβ amyloid PET imaging, MRI, CSF, biomarkers, and RSfMRI are candidates for selecting at risk patients for AD.(1)
These processes detect prevention treatments or delaying the progression of AD.(1)
Amyloid precursor protein, presenilin-1 (PSEN1), presenilin-2 (PSEN2), and APOE gene mutations are the important
risk factors in Alzheimer.(2)
Having a genetic variant of the apolipoprotein E (APOE) gene on chromosome 19 increases the risk of
getting AD.(2)
The pathology of Alzheimer diseases is dominated by extracellular AB deposits.((2)2)
MRS provides insight into the metabolic alterations imposed on by neuronal degeneration and other
neurodegenerative pathologies.(2)

• Each biomarker differed due to their continual
alteration in disease progression. (1)
• Neurodegeneration occurred in the hippocampus.
(1)

• Atrophy occurred in later stages, spreading to the
parietal, occipital, and frontal lobes. (1)
• MRS is a potential biochemical imaging marker in
AD.(2)
• Hippocampal atrophy alterations provide accurate
MRI
• markers for AD.(2)

UNDERSTANDING THE HISTORY OF IMAGING DATA ADVANCE.(2)
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Figure 2. Typical cortical volume of healthy individual (A-C)
top row compared with severe volume loss seen in a person with
advanced Alzheimer’s disease (AD) with enlarged ventricles, and
loss of volume in the gyri and hippocampus.(3)
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METHOD

• We were able to utilize research-based projects from
meta-analysis acquisitions.
• Research is taken from MRI images and papers from
the ADNI database collected from multiple imaging
centers.
• We were able to preform data analysis using
Gadolinium and Iodine filters as a contrast medium for
MRI studies.

The era of imaging booming on Alzheimer’s disease depended on MRI
magnets of 1.5T and 3T, from the developing of the first phase ADNI-MRI
parameter has been adjusted to be compatible with the latest phase call
ADNI-3 which took place in the mid 2017’, regardless of the vendor GE,
Siemens and Phillips all protocols from the second phase ADNI-2 are used
on the third phase ADNI-3 in 3 Tesla models. The differences are
exclusive in the names of sequences corresponding to each vendor due to
owner licenses. The functionality of ADNI is adapted in advance protocols
imaging of phase-3, being the most critical uses for detection of
Alzheimer’s disease are T1 weighted, ASL, MP-RAGE, T2* GRE, 3D- FLAIR
and High Res Hippo, DWI and EPI-BOLD. The advance in brain DWI and RS
fMRI cohesion is accomplished with the use EPI, post processing done
gaining time and converging to match the images mentioned. Regardless
of the MRI advances in diseases, images still take approximately 4-10
minutes.
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